Home   Business   Article

Abcam expands custom capabilities with acquisition of California-based Calico Biolabs

By Paul Brackley

Abcam has acquired California-based antibody company Calico Biolabs.

Abcam is building its new HQ on Cambridge Biomedical Campus
Abcam is building its new HQ on Cambridge Biomedical Campus

The Cambridge life science research tools firm said the purchase expanded its custom services capabilities.

Calico is a developer of high-quality recombinant rabbit monoclonal antibodies for diagnostic and biopharmaceutical companies.

It brings with it a small catalogue of ready-made CAL antibodies for immunohistochemistry (IHC) along with custom development services. Its products will be made available via the Abcam global commercial network.

John Baker, SVP of product portfolio and innovation at Abcam, said: “The acquisition of Calico represents execution of our strategy to provide the best and highest quality products to our diagnostic, biopharmaceutical and research customers.

“By incorporating Calico’s product portfolio and custom services, Abcam expands its offering of rabbit monoclonals for IHC, allowing development of more products for their most important targets, faster.

“We are excited to welcome the Calico team to the Abcam family, furthering Abcam’s mission to provide customers with the highest quality recombinant antibodies for their research.”

Jacinto Villanueva, CEO of Calico, said: “Abcam is a recognised leader for the supply of high-quality validated antibodies, supported by an innovative approach to production and commercialisation, and we are excited to be joining the team.

“This move will enable us to more fully support the cancer research and associated diagnostics development being carried out by our industry partners.”

The terms of the deal have not been disclosed but Abcam said there would be “minimal impact on revenue and earnings” for the financial year.

Read more

Abcam collaborates with Loulou Foundation to accelerate research into CDKL5 deficiency disorder

Abcam ends interest in Horizon Discovery after £270m bid rejected

Abcam expects double digit revenue growth


Iliffe Media does not moderate comments. Please click here for our house rules.

People who post abusive comments about other users or those featured in articles will be banned.

Thank you. Your comment has been received and will appear on the site shortly.


Terms of Comments

We do not actively moderate, monitor or edit contributions to the reader comments but we may intervene and take such action as we think necessary, please click here for our house rules.

If you have any concerns over the contents on our site, please either register those concerns using the report abuse button, contact us here.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More